| Trial ID: | L0842 |
| Source ID: | IRCT2015122125641N1
|
| Associated Drug: |
Cynarol
|
| Title: |
Effect of Cyanrol in treatment of Non-alcoholic fatty liver disease: a randomized double-blind clinical trial including plaebo
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Fatty liver. <br>?Fatty (change of) liver, not elsewhere classified;?Fatty (change of) liver, not elsewhere classified
|
| Interventions: |
Intervention 1: Cynarol,200 mg oral tablet, 3 times a day for 8 weeks. Intervention 2: placebo,200mg oral tablet,3 times a day for 8 weeks.;Treatment - Drugs;Placebo;Cynarol,200 mg oral tablet, 3 times a day for 8 weeks;placebo,200mg oral tablet,3 times a
|
| Outcome Measures: |
The accumulation of liver fat. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Color Doppler Ultrasonography.LDL. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;HDL. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;Portal vein diameter. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Color Doppler Ultrasonography.;TG. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;Total Cholesterol. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;FBS. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;HbA1C. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;Uric Acid. Timepoint: Before the intervention, 8weeks later at the end of the intervention. Method of measurement: Blood test.;Hepatic blood flow velocity. Timepoint: before the intervention8weeks later at the end of intervention. Method of measurement: Color Doppler Ultrasonography.;ALT. Timepoint: before the intervention,8 weeks later at the end of intervention. Method of measurement: Blood test.;AST. Timepoint: before the intervention,8 weeks later at the end of intervention. Method of measurement: Blood test.
|
| Sponsor/Collaborators: |
Vice chancellor for research of Baqiyatallah University of Medical Science
|
| Gender: |
All
|
| Age: |
18 years139 years
|
| Phases: |
Phase 2/Phase 3
|
| Enrollment: |
100
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: It is a double-blind clinical trail in which neither patients nor analysis technician have no information about the kind o
|
| Start Date: |
31/08/2016
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/21398
|
